Adults 50 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral CreatinePrimary· 12 weeks
Estimated mean change from baseline in the ratio of cerebral NAA/ cerebral Creatine as measured by MRI Spectroscopy.
Group
Value
95% CI
Dapagliflozin
1.49
± 0.11
Matching Placebo
1.42
± 0.09
Adverse events — posted to ClinicalTrials.gov
Time frame: Data was collected from week 0 to week 12.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a pilot randomized controlled trial in individuals with probable Alzheimer's disease testing the effects of 10 mg dapagliflozin, taken daily for 12 weeks, on cerebral n-acetyl aspartate (NAA) levels using magnetic resonance spectroscopy (MRS). The investigators will also examine the safety and tolerability of dapagliflozin and explore the effects on systemic NAA levels in blood and urine, cerebral metabolism (fluorodeoxyglucose \[FDG\] PET), systemic metabolic biomarkers that indicate and quantify secondary metabolic effects, and cognitive performance.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
· Phase 4
· active not recruiting
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
NCT07290387 — Tele-Savvy for Latino Caregivers
· NA
· recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
· NA
· recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease
· NA
· recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
· Phase 3
· recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jeff Burns, MD
Last refreshed: 13 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03801642.